These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 10942175)
1. Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy. Hassan M; Svensson JO; Nilsson C; Hentschke P; Al-Shurbaji A; Aschan J; Ljungman P; Ringdén O Ther Drug Monit; 2000 Aug; 22(4):383-5. PubMed ID: 10942175 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Slattery JT; Risler LJ Ther Drug Monit; 1998 Oct; 20(5):543-9. PubMed ID: 9780133 [TBL] [Abstract][Full Text] [Related]
3. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Mannis GN; Andreadis C; Logan AC; Damon LE; Benet LZ; Ai WZ; Gaensler KM; Kaplan LD; Koplowicz YB; Linker CA; Olin RL; Sayre PH; Smith CC; Sudhindra A; Venstrom JM; Wolf JL; Martin TG Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):377-83. PubMed ID: 25776193 [TBL] [Abstract][Full Text] [Related]
4. Busulfan and metronidazole: an often forgotten but significant drug interaction. Gulbis AM; Culotta KS; Jones RB; Andersson BS Ann Pharmacother; 2011 Jul; 45(7-8):e39. PubMed ID: 21730282 [TBL] [Abstract][Full Text] [Related]
5. [Morphine, pethidine or ketobemidone in acute pain--are there significant differences?]. Rygnestad T; Slørdal L Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2548-9. PubMed ID: 11070995 [No Abstract] [Full Text] [Related]
6. The opioid ketobemidone has a NMDA blocking effect. Andersen S; Dickenson AH; Kohn M; Reeve A; Rahman W; Ebert B Pain; 1996 Oct; 67(2-3):369-74. PubMed ID: 8951931 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation. Hilger RA; Baumgart J; Scheulen ME; Trenschel R; Strumberg D; Seeber S; Beelen DW Int J Clin Pharmacol Ther; 2004 Nov; 42(11):654-5. PubMed ID: 15598037 [No Abstract] [Full Text] [Related]
9. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram. Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238 [TBL] [Abstract][Full Text] [Related]
10. Disposition of treosulfan and its active monoepoxide in a bone marrow, liver, lungs, brain, and muscle: Studies in a rat model with clinical relevance. Romański M; Kasprzyk A; Walczak M; Ziółkowska A; Główka F Eur J Pharm Sci; 2017 Nov; 109():616-623. PubMed ID: 28916482 [TBL] [Abstract][Full Text] [Related]
11. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H; Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446 [TBL] [Abstract][Full Text] [Related]
12. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410 [TBL] [Abstract][Full Text] [Related]
13. Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. Shimoni A; Labopin M; Savani B; Hamladji RM; Beelen D; Mufti G; Socié G; Delage J; Blaise D; Chevallier P; Forcade E; Deconinck E; Mohty M; Nagler A Biol Blood Marrow Transplant; 2018 Apr; 24(4):751-757. PubMed ID: 29247780 [TBL] [Abstract][Full Text] [Related]
14. Patient-controlled analgesic therapy, Part III: pharmacokinetics and analgesic plasma concentrations of ketobemidone. Tamsen A; Bondesson U; Dahlström B; Hartvig P Clin Pharmacokinet; 1982; 7(3):252-65. PubMed ID: 7094500 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611 [TBL] [Abstract][Full Text] [Related]
16. Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. de Castro FA; Lanchote VL; Voltarelli JC; Colturato VA; Simões BP J Clin Pharmacol; 2013 Nov; 53(11):1205-11. PubMed ID: 23955479 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics after a single intravenous dose of the opioid ketobemidone in neonates. Lundeberg S; Stephanson N; Stiller CO; Eksborg S Acta Anaesthesiol Scand; 2012 Sep; 56(8):1026-31. PubMed ID: 22834454 [TBL] [Abstract][Full Text] [Related]
18. Single-dose kinetics and bioavailability of ketobemidone. Anderson P; Arnér S; Bondesson U; Boréus LO; Hartvig P Acta Anaesthesiol Scand Suppl; 1982; 74():59-62. PubMed ID: 6124079 [TBL] [Abstract][Full Text] [Related]
19. Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan. Galaup A; Paci A Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):333-47. PubMed ID: 23157726 [TBL] [Abstract][Full Text] [Related]
20. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia. Baker KS; Bostrom B; DeFor T; Ramsay NK; Woods WG; Blazar BR Bone Marrow Transplant; 2000 Sep; 26(6):607-14. PubMed ID: 11041565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]